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The present study evaluated the antioxidant activity and potential toxicity of 50% methanolic extract of Orthosiphon stamineus
(Lamiaceae) leaves (MEOS) after acute and subchronic administration in rats. Superoxide radical scavenging, hydroxyl radical
scavenging, and ferrous ion chelating methods were used to evaluate the antioxidant properties of the extract. In acute toxicity
study, single dose of MEOS, 5000mg/kg, was administered to rats by oral gavage, and the treated rats were monitored for 14
days. While in the subchronic toxicity study, MEOS was administered orally, at doses of 1250, 2500, and 5000mg/kg/day for 28
days. From the results, MEOS showed good superoxide radical scavenging, hydroxyl radical scavenging, ferrous ion chelating,
and antilipid peroxidation activities. There was no mortality detected or any signs of toxicity in acute and subchronic toxicity
studies. Furthermore, there was no significant difference in bodyweight, relative organ weight, and haematological and biochemical
parameters between bothmale and female treated rats in any doses tested. No abnormality of internal organs was observed between
treatment and control groups.The oral lethal dose determined wasmore than 5000mg/kg and the no-observed-adverse-effect level
(NOAEL) of MEOS for both male and female rats is considered to be 5000mg/kg per day.
1. Introduction
Herbal medicines have received a great deal of attention as
alternative medicines in recent years inMalaysia and are sold
as dietary supplements. One of the Malaysian local herbs,
scientifically known as Orthosiphon stamineus Benth (Lami-
aceae) or locally called Misai Kucing, has attracted much
attention for research purposes.Orthosiphon stamineus is also
found in other countries such as Thailand, Indonesia, and
Europe. It is widely used for the treatment of many diseases,
especially those affecting the urinary tract, diabetes mellitus,
hypertension, rheumatism, tonsillitis, and menstrual disor-
ders [1]. The benefits of the traditional use of Orthosiphon
stamineus have also been supported by the isolation and
identification of several possible active chemical constituents
from this plant, including flavonoids [2, 3], terpenoids [4,
5], saponins, hexoses, organic acids, caffeic acid derivatives,
chromene, and myo-inositol [4–6]. Among the reported
compounds, the most important components ofOrthosiphon
stamineus leaves are the polyphenols; polymethoxylated
flavonoids such as sinensetin and eupatorine; caffeic acid
derivatives, which include rosmarinic acid, cichoric acid, and
caffeic acid [6].
Notwithstanding the widespread and long time usage
of this plant, little toxicological information is available
regarding the safety following chronic consumption of O.
stamineus especially the bioactive 50% methanolic extract
which has been reported to be effective in protection against
alcohol-induced gastropathy, CCl
4
-induced liver damage,
antipyretic, anti-inflammatory, and analgesic effects [7–10].
Currently, Malaysian authorities are paying more and more
attention on the safety and potential toxicity of botanicals,
including medicinal plants and edible materials. Therefore,
the aims of the present study were to evaluate the antioxidant
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and provide scientific data on the safety of O. stamineus,
focusing on the 14-day acute and 28-day subchronic toxicity
of bioactive 50% methanolic extract of O. stamineus, using
Sprague-Dawley (SD) rats, and hence, providing guidance for
selecting a safe dose of O. stamineus in its use as a traditional
medicine.
2. Materials and Methods
2.1. Chemical. Ferrous chloride (FeCl
2
), hematoxylin,
ferrozine, 2-deoxyribose, ethylenediaminetetraacetic acid
(EDTA), ferrous sulfate (FeSO
4
), trichloroacetic acid (TCA),
nitroblue tetrazolium (NBT), xanthine, xanthine oxidase
sodiumphosphate (dibasic), sodiumphosphate (monobasic),
butylated hydroxytoluene (BHT), butylated hydroxyanisole
(BHA), manganese chloride, xylenol orange, manganese
chloride, and sodium dihydrogen phosphate (NaH
2
PO
4
)
were purchased from Sigma (St. Louis, MO, USA). Absolute
alcohol and eosin were purchased from Riedel-de Hae¨n
(Seelze, Germany). Paraplast was purchased from Oxford
Labware (St. Louis, MO, USA). Xylene was purchased from
Fisher Scientific (Leics, UK). Disposable microtome blades
818 were purchased from LEICA (Germany). Thiobarbituric
acid (TBA) was purchased from AppliChem (Darmstadt,
Germany). 3󸀠-hydroxy-5,6,7,4󸀠-tetramethoxyflavone, sinen-
setin, and eupatorin were obtained from Indofine Chemical
Company (NJ, USA). HPLC-grade acetonitrile and isopropyl
alcohol were purchased fromMerck (Darmstadt, Germany).
2.2. Plant Materials and Extract. Orthosiphon stamineus was
grown from cuttings using standard agronomic practices at
Kepala Batas, Pulau Pinang, Malaysia. The leaves of the plant
were collected after flowering. The leaves were identified by
Mr. Adenan Jaafar, School of Biological Sciences, Universiti
Sains Malaysia. A voucher specimen (number 10810) was
deposited at the Herbarium of School of Biological Sciences,
Universiti Sains Malaysia. The leaves were rinsed and dried
in oven at 40∘C for 2 days.The dried leaves were then ground
by an electric grinder to a coarse powder and weighed.
Subsequently, 300 g of powdered leaves of O. stamineus
was extracted with 5 L methanol : water (50 : 50 v/v) at 60∘C
(for 8 hours) by maceration method. The resulting 50%
methanolic extract of O. stamineus (MEOS) was concen-
trated using a Bu¨chi-RE121 evaporator (Bu¨chi Laboratorium-
Technik, Switzerland) equipped with a Bu¨chi-B169 vacuum
system and then lyophilized in a Hetovac VR-1 (HETO Lab
Equipment, Denmark) freeze dryer.The weight of the MEOS
was recorded and the final plant-to-extract ratio was about
6%. The MEOS was then kept in desiccators in a refrigerator
(0–4∘C). The MEOS was freshly prepared daily by dissolving
in distilled water.
2.3. HPLC Study
2.3.1. HPLC Instrumentation. HPLC analysis was performed
using a Shimadzu-LC system (Shimadzu, Japan) equipped
with a CBM-20A controller, LC-20AT pump, DGU-20A5
degasser, SIL-20A autosampler, SPD-20AV detector, and
CTO-10ASvp column oven.
2.3.2. Chromatographic Conditions. Chromatographic sepa-
rations were achieved using an Agilent Eclipse Plus C18 (250
× 4.6mm i.d.; 5 𝜇m). A Zorbax guard fittings kit packed with
replaceable Eclipse Plus C18 Guard column (12.5 × 4.6mm
i.d.; 5 𝜇m) was used to protect the analytical column. A
reverse-phase HPLC assay was carried out using an isocratic
system with a flow rate of 1mL/min, a column temperature
of 25∘C, and a mobile phase of acetonitrile : isopropyl alco-
hol : 20mM phosphate buffer (NaH
2
PO
4
) (30 : 15 : 55 v/v),
with pH adjusted to 3.5 using 85% phosphoric acid. The
UV detection was set at 340 nm. The injection volume was
20𝜇L of solution. Total run time was less than 20min for
each injection. Data was acquired and processed with LC-
Solution software. The peaks were detected at 340 nm and
identified using reference standards of 3󸀠-hydroxy-5,6,7,4󸀠-
tetramethoxyflavone, sinensetin, and eupatorin. Sinensetin
and eupatorin were selected as standards because these two
compounds were found to be the bioactive ingredients in the
plant [11–13].
2.4. Antioxidant
2.4.1. Ferrous Ion Chelating Activity. Ferrous chelating activ-
ity was determined according to the method of Dinis et
al. [14]. MEOS was added to a solution of 0.05mL ferrous
chloride (FeCl
2
) (2mM). The reaction was initiated by the
addition of 0.2mL ferrozine (5mM) and the mixture was
shaken vigorously and left standing at room temperature
(24 ± 2∘C) for 10min. Absorbance of the solution was then
measured spectrophotometrically (U-2000,Hitachi, Japan) at
wavelength 562 nm.Thepercentage of inhibition of ferrozine-
Fe2+ complex formation was calculated using the following
formula:
Ferrous ion chelating activity = [
(𝐴
0
− 𝐴
1
)
𝐴
0
] × 100,
(1)
where 𝐴
0
was the absorbance of the control and 𝐴
1
was
the absorbance in the presence of extracts. The experiment
was run together with butylated hydroxytoluene (BHT) and
butylated hydroxyanisole (BHA) as positive controls.
2.4.2. Hydroxyl Radical Scavenging Activity. Competition
between deoxyribose and the extract against hydroxyl radical
generated from the Fe3+/ascorbate/ethylenediaminetetraace-
tic acid (EDTA)/hydrogen peroxide (H
2
O
2
) system was mea-
sured to determine the hydroxyl radical scavenging activity
of MEOS [15]. The reaction mixture consisted of 0.30mL
of 0.02M sodium phosphate buffer (pH 7.0), 0.15mL of
10mM 2-deoxyribose, 0.15mL of 10mM FeSO
4
, 0.15mL of
10mMEDTA, 0.15mL of 10mMH
2
O
2
, 0.525mL ofH
2
O, and
0.075mL of extract. The reaction mixture was incubated at
37∘C for 2 h and the formed TBARS were measured. Seventy
five milliliter of 2.8% trichloroacetic acid and 0.75mL of 1.0%
TBA in 50mMNaOHwere added to test tubes and boiled for
20min. After cooling the mixture, absorbance was measured
at 520 nm. The percentage of inhibition of inhibition rate of
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2-deoxyribose oxidation by hydroxyl radical was given in the
following formula:
Hydroxyl radical scavenging activity =[
(𝐴
0
− 𝐴
1
)
𝐴
0
]× 100,
(2)
where 𝐴
0
was the absorbance of the control and 𝐴
1
was the
absorbance in the presence of extracts.
2.4.3. Superoxide Anion Radical Scavenging Activity. Super-
oxide anion radical generated by the xanthine/xanthine
oxidase system was determined spectrophotometrically by
monitoring the product of nitroblue tetrazolium (NBT) [16].
The reactionmixture consisted of 1.0mL of 0.05M phosphate
buffer (pH 7.4), 0.04mL of 3mM xanthine, 0.04mL of 3mM
EDTA, 0.04mL of 0.15% bovine serum albumin, 0.04mL of
15mM NBT, and 0.04mL of sample solution. After incuba-
tion at 25∘C for 10min, the reaction was initiated by adding
0.04mL of 1.5 U/mL xanthine oxidase and carried out at
25∘C for 20min. After 20min, the absorbance of the reaction
mixture was measured at 560 nm. Decreased absorbance of
the reaction mixture indicates increased superoxide anion
radical scavenging activity.
2.4.4. Lipid Peroxidation Inhibition Study. Fresh livers were
obtained from healthy male adult SD rats. They were then
homogenized according to the method [17] for the prepara-
tion of 40% (w/v) liver homogenates in methanol. 80 𝜇L of
liver homogenate was mixed with 10 𝜇L of Fenton’s reagent
(containing 5𝜇L of 5mM manganese chloride and 5 𝜇L of
50mM hydrogen peroxide) and 10𝜇L of various concentra-
tions of MEOS (for control, the extract was replaced with
distilled water). The mixture was incubated for 30min at
37∘C to produce lipid peroxidation. The mixture was then
added with 900mL FOX reagent (containing 49mg ammo-
nium ferrous sulfate in 50mL of 250mM H
2
SO
4
, 0.397 g of
BHT, and 0.038 g of xylenol orange in 950mL methanol).
Absorbance of themixture was read at 560 nm after 30min of
incubation at room temperature.The percentage of inhibition
was calculated with the following equation:
% of inhibition = [
(𝐴
0
− 𝐴
1
)
𝐴
1
] × 100, (3)
where 𝐴
0
was the absorbance in the presence of extracts and
𝐴
1
was the absorbance of the control.
2.5. Toxicology Studies
2.5.1. Experimental Animals. Eight-week-old male and
female Sprague-Dawley rats (160–190 g)were purchased from
the Animal House, School of Pharmaceutical Sciences, Uni-
versiti Sains Malaysia. The rats were acclimatised to labo-
ratory conditions for 7 days prior to performing the experi-
ments. All rats were kept at 26 ± 3∘C, with a light/dark cycle
of 12 hours. The rats were housed in a single polycarbonate
cage (3 rats per cage) with free access to food (normal
laboratory chow, Gold Coin) and tap water ad libitum. All
the procedures were performed according to the Animal
Ethics Guidelines of Universiti Sains Malaysia.
2.5.2. Acute Toxicity Study. The experiment was performed
according to the Organisation for Economic Cooperation
and Development (OECD) revised up and down procedure
for acute toxicity testing [18]. All the rats were fasted
overnight and weighed before the extract was administered.
A maximum dose of 5000mg/kg of MEOS was administered
by oral gavage to 5 healthy female adult Sprague-Dawley
rats. The administration volume was adjusted between 1
and 2mL for each and every rat. After administration of
MEOS to the first rat, the rat was observed for clinical signs
of toxicity for the first hour, then hourly for three hours,
and then periodically throughout 48 hours. Other rats were
administrated sequentially at 48-hour intervals if the first rat
survived after 48 hours of treatment. All the experimental rats
were maintained under close observation throughout the 14
days and the number of mortality was recorded. The LD
50
was predicted to be above 5000mg/kg if three or more rats
survived after the experimental period [19].
2.5.3. Subchronic Toxicity Study. Experimental Sprague-
Dawley rats of either sex were randomly assigned to 4
groups (𝑛 = 12; six males and six females per group),
and their weights were recorded. Different doses of MEOS
(1250, 2500, or 5000mg/kg) were prepared in distilled water
and administered daily as single doses to different groups
of rats: group 1 (5000mg/kg), group 2 (2500mg/kg), and
group 3 (1250mg/kg), while group 4 (control) received
only distilled water. Toxic manifestations and mortality were
monitored daily for 28 days. The bodyweights of all the
rats were measured and recorded at the end of every week
and the treated rats were anesthetised using CO
2
after 28
days of treatment. Blood samples were collected via cardiac
puncture and transferred into nonheparinised and EDTA-
containing tubes for both biochemical and haematological
analyses, respectively [20]. Thereafter, the rats were killed by
cervical dislocation. All organs, brain, heart, lungs, thymus,
liver, kidneys, adrenal glands, sex organs (ovaries and uterus
for female rats; testes for male rats), spleen, stomach, and
gut (begining from small intestine until the end of large
intestine), of all experimental rats were excised, weighed,
and examined macroscopically. Vital organs such as lungs,
kidneys, livers, and stomach were then preserved in 10%
formalin for histopathological study [19].
2.5.4. Relative Organ Weight. The excised organs were
weighed individually. The relative organ weight index of
each organ to its bodyweight was calculated as (weight of
organ/bodyweight of rats on the day of sacrifice) × 100% [20].
2.5.5. Blood Analyses. Haematological and biochemical anal-
yses were performed at the Pathology Laboratory, Lam
Wah Ee Hospital, Penang. Complete blood cell counts were
determined using a fully automated haematological analyser
Abbott Cell-Dyn 3500 (Abbott Laboratories, IL, USA), while
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Figure 1: Ferrous ion chelating activity of MEOS (𝑛 = 3). Data are
expressed as mean ± SD.
serum biochemistry tests were performed using a COBAS
Integra 800 (Roche, Germany) [20].
2.5.6. Histopathological Study. Vital organs (kidney and liver)
were processed using a Citadel 1000 Histokinette (Shandon
Scientific Ltd., Cheshire, UK). These tissues were embedded
in paraffinusing aHisto-Center II-N (Barnstead/Thermolyne
Corp., Dubuque, IA, USA) and cut into 5 𝜇m thick sections
with a Reichert-Jung Histocut 820 II (Cambridge Instrument
GmbH, Nussloch, Germany). All the sections were stained
with haematoxylin and eosin and examined microscopically
[20].
2.6. Statistical Analysis. Statistical analysis was carried out
using the Statistical Package for Social Sciences (SPSS). All
the data are indicated as mean ± standard error of mean
(SEM) and were analysed using one-way analysis of variance
(ANOVA). Significant differences between the groups were
determined using a Dunnett-comparison test with 𝑃 < 0.05
taken as significant.
3. Results
3.1. HPLC Analysis. The objective of HPLC analysis in this
experiment was to standardize the MEOS using sinensetin,
eupatorin, and3󸀠-hydroxy-5,6,7,4󸀠-tetramethoxyflavone. From
the results, the percentages of sinensetin, eupatorin, and 3󸀠-
hydroxy-5,6,7,4󸀠-tetramethoxyflavone determined in MEOS
were 1.12 ± 0.026%, 0.94 ± 0.025%, and 0.46 ± 0.016% (w/w),
respectively.
3.2. Antioxidant Activities
3.2.1. Ferrous Ion Chelating Activity. Ferrozine can quantita-
tively form the complexes with Fe2+. Chelating activity of the
MEOSwith ferrous ion was 1.6% at 0.125mg/mL. In addition,
there was an increase of chelating activity to 30% at 2mg/mL
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Figure 2: Hydroxyl radical scavenging activity of MEOS (𝑛 = 3).
Data are expressed as mean ± SD.
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Figure 3: Superoxide radical scavenging activity of MEOS (𝑛 = 3).
Data are expressed as mean ± SD.
which was slightly lower than positive control (BHA and
BHT) (Figure 1).
3.2.2. Hydroxyl Radical Scavenging Activity. The hydroxyl
radical scavenging activity was investigated by using the
Fenton reaction. As shown in Figure 2, addition of less than
2mg/mL of MEOS effectively inhibited the formation of
hydroxyl radicals linearly up to 72%.
3.2.3. Superoxide Anion Radical Scavenging Activity. Super-
oxide anion radical scavenging activity of MEOS was deter-
mined by the xanthine oxidase system. Figure 3 showed
the percentage inhibition of superoxide radical gener-
ated by BHT, BHA, and MEOS. The inhibition activity
of MEOS reached 63% when 2mg/mL of extract was
used.
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Figure 4: The effect of daily oral administration of MEOS on the bodyweight of (a) male and (b) female rats (𝑛 = 6). Data are expressed as
mean ± SEM.
3.2.4. Lipid Peroxidation Inhibition Study. Antilipid peroxi-
dation activity ofMEOSwas determined by the FOXmethod.
IC
50
of liver homogenate lipid peroxidation of MEOS was
0.34 ± 0.024mg/mL.
3.3. Toxicology Studies
3.3.1. Acute Toxicity Study. In this experiment, oral admin-
istration of 5000mg/kg of MEOS did not cause any visible
signs of toxicity to the rats. No changes were observed in the
behavior and mortality of the animals over the 14 days. All
five female SD rats survived until the end of the experiment
with no mortality were recorded. The LD
50
determined was
greater than 5000mg/kg.
3.3.2. Subchronic Toxicity Study. In subchronic toxicity study,
there were no observable changes in the general behaviour
of all the treated rats (groups 1, 2, and 3) as compared to the
control group. No significant changes were detected in either
the bodyweights (Figure 4) or relative organweights (Table 1)
of all the treated rats. In addition, no death was recorded in
both sexes of the treatment groups as well as their respective
control group, during or after the course of the experiment.
The controls and the treated rats appeared uniformly healthy
at the end of the experiment and throughout the 28 days
treatment period.
3.3.3. Blood Analyses. There were no significant differences
observed in any of the haematological parameters tested
(red blood cell count (RBC), haemoglobin concentration
(Hgb), haematocrit (Ht), mean corpuscular volume (MCV),
mean corpuscular haemoglobin (MCH), mean corpuscular
haemoglobin concentration (MCHC), total white blood cell
count (WBC), or white blood cell differential count) in any
of the treated rats as compared to control rats (Table 2).
Meanwhile, analyses of biochemical parameters (alanine
transaminase (ALT), aspartate transaminase (AST), alka-
line phosphatase (ALP), creatinine, bilirubin, urea, sodium,
potassium, and chlorine) also showed no significant differ-
ences in any of the parameters tested between the control and
the treated groups of both sexes (Table 3).
3.3.4. Histopathological Study. No lesions or pathological
changes were observed in the organs of either sex of the
MEOS treated rats as compared to their respective control
groups.
4. Discussion
Orthosiphon stamineus Benth. (Lamiaceae) is an important
medicinal plant in Malaysia. It has been widely used for
treatment of various ailments. Many studies which involved
both in vivo and in vitro experiments have reported that the
Orthosiphon stamineus leaves possess a wide range of phar-
macological properties such as, anti-inflammatory, analgesic,
gastroprotective, antipyretic, and hepatoprotective effects.
The present study was conducted to determine the antiox-
idant potential, which is responsible for the wide range of
pharmacological properties of this plant and to investigate the
possible harmful effects of MEOS in experimental animals at
the specific doses chosen, since the safety use of the plant is of
concern to the Malaysian authorities. The toxicity of MEOS
in rats was evaluated by both acute 14-day and subchronic
28-day toxicological studies. Methanol was chosen as our
solvent since many literature reviews showed that this extract
was very effective in many pharmacological activities such as
antipyretic, anti-inflammatory, and analgesic effects as well as
a good protective agent against alcohol-induced gastropathy
and CCl
4
-induced liver damage [7–10].
Antioxidant capacity is one of the commonly used param-
eters to determine the bioactive components which exhibited
pharmacological activities. Orthosiphon stamineus has been
shown to be a potent scavenger of a variety of reactive
radical species such as DPPH and ABTS [7].Therefore, in the
present study, the antioxidant potential of MEOS was tested
by Ferrous ion chelating activity, hydroxyl radical scavenging
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Table 1: (a) Relative organs weight of male rats orally treated daily with 50% methanolic extract of Orthosiphon stamineus for 28 days. (b)
Relative organs weight of female rats orally treated daily with 50% methanolic extract of Orthosiphon stamineus for 28 days (cont’).
(a)
% organ weight/bodyweight
Treatment for 28 days
Control 50% methanolic extract of Orthosiphon stamineus
1250mg/kg 2500mg/kg 5000mg/kg
Male
Brain 0.42 ± 0.02 0.39 ± 0.01 0.43 ± 0.02 0.42 ± 0.02
Heart 1.54 ± 0.03 1.44 ± 0.13 1.43 ± 0.08 1.37 ± 0.06
Liver 2.34 ± 0.10 2.42 ± 0.16 2.48 ± 0.15 2.46 ± 0.14
Thymus 0.14 ± 0.01 0.16 ± 0.01 0.15 ± 0.01 0.15 ± 0.01
Spleen 0.27 ± 0.02 0.27 ± 0.01 0.25 ± 0.01 0.27 ± 0.02
Kidney (right) 0.35 ± 0.01 0.37 ± 0.02 0.33 ± 0.01 0.35 ± 0.01
Kidney (left) 0.32 ± 0.01 0.33 ± 0.01 0.32 ± 0.01 0.33 ± 0.01
Adrenal gland 0.01 ± 0.00 0.02 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
Lungs 0.67 ± 0.05 0.71 ± 0.06 0.63 ± 0.02 0.63 ± 0.03
Testis (right) 0.56 ± 0.02 0.54 ± 0.01 0.55 ± 0.01 0.55 ± 0.02
Testis (left) 0.54 ± 0.03 0.55 ± 0.01 0.54 ± 0.02 0.56 ± 0.01
Stomach 2.74 ± 0.31 2.63 ± 0.06 2.93 ± 0.08 2.56 ± 0.11
Stomach (empty) 0.57 ± 0.01 0.59 ± 0.01 0.51 ± 0.02 0.54 ± 0.02
Gut 6.64 ± 0.21 6.38 ± 0.14 6.45 ± 0.14 6.32 ± 0.30
Gut (empty) 3.27 ± 0.03 3.44 ± 0.11 3.17 ± 0.04 3.24 ± 0.13
Data are expressed as mean ± SEM.
(b)
% organ weight/bodyweight
Treatment for 28 days
Control 50% methanolic extract of Orthosiphon stamineus
1250mg/kg 2500mg/kg 5000mg/kg
Female
Brain 0.40 ± 0.00 0.39 ± 0.00 0.40 ± 0.01 0.38 ± 0.01
Heart 1.70 ± 0.03 1.65 ± 0.02 1.68 ± 0.02 1.60 ± 0.04
Liver 2.61 ± 0.08 2.69 ± 0.09 2.81 ± 0.04 2.66 ± 0.06
Thymus 0.11 ± 0.01 0.09 ± 0.01 0.09 ± 0.00 0.10 ± 0.01
Spleen 0.22 ± 0.01 0.25 ± 0.02 0.23 ± 0.02 0.24 ± 0.01
Kidney (right) 0.28 ± 0.01 0.27 ± 0.01 0.28 ± 0.01 0.26 ± 0.01
Kidney (left) 0.27 ± 0.00 0.27 ± 0.01 0.28 ± 0.00 0.26 ± 0.01
Adrenal gland 0.02 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 0.02 ± 0.00
Lungs 0.66 ± 0.01 0.63 ± 0.02 0.65 ± 0.02 0.67 ± 0.03
Ovaries 0.13 ± 0.01 0.09 ± 0.01 0.10 ± 0.01 0.11 ± 0.01
Uterus 0.21 ± 0.00 0.16 ± 0.01 0.19 ± 0.02 0.15 ± 0.01
Stomach 2.74 ± 0.18 2.71 ± 0.14 2.71 ± 0.06 2.69 ± 0.09
Stomach (empty) 0.58 ± 0.01 0.53 ± 0.01 0.51 ± 0.01 0.50 ± 0.01
Gut 7.29 ± 0.25 6.82 ± 0.21 6.80 ± 0.11 6.94 ± 0.30
Gut (empty) 4.06 ± 0.08 3.83 ± 0.11 3.63 ± 0.13 3.82 ± 0.15
Data are expressed as mean ± SEM.
activity, and superoxide anion radical scavenging activity.
Our study showed that the antioxidant activity of MEOS was
comparable to the positive controls: BHA and BHT. In the
antioxidant activities, we reported that MEOS can strongly
reduce the hydroxyl and supercritical onion radicals. This
finding is comparable to the previous study which reported
that MEOS inhibited lipid peroxidation in different animal
models [7, 10]. In addition, it has been long reported that
there is a strong association between the termination of free
radical propagation in biological systems with the reduction
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Table 2: (a) Haematological values ofmale rats treated with 50%methanolic extract ofOrthosiphon stamineus for 28 days. (b) Haematological
values of female rats treated with 50% methanolic extract of Orthosiphon stamineus for 28 days (cont’).
(a)
Unit
Treatment for 28 days
Control 50% methanolic extract of Orthosiphon stamineus
1250mg/kg 2500mg/kg 5000mg/kg
Male
White blood cell count 109/L 9.57 ± 0.32 11.05 ± 0.48 10.78 ± 0.59 10.73 ± 0.21
Neutrophils 109/L 2.46 ± 0.18 3.09 ± 0.22 3.15 ± 0.31 3.18 ± 0.43
Lymphocytes 109/L 6.67 ± 0.24 6.94 ± 0.46 6.72 ± 0.29 6.67 ± 0.41
Monocytes 109/L 0.24 ± 0.03 0.62 ± 0.09 0.53 ± 0.15 0.54 ± 0.05
Eosinophils 109/L 0.02 ± 0.00 0.04 ± 0.01 0.05 ± 0.01 0.05 ± 0.01
Basophils 109/L 0.18 ± 0.03 0.35 ± 0.04 0.33 ± 0.08 0.30 ± 0.02
Red blood cell count 1012/L 8.55 ± 0.12 8.36 ± 0.17 8.43 ± 0.20 8.24 ± 0.03
Hemoglobin g/L 14.80 ± 0.21 14.76 ± 0.14 15.02 ± 0.32 14.49 ± 0.08
Hematocrit % 0.75 ± 0.01 0.74 ± 0.02 0.75 ± 0.02 0.71 ± 0.00
Mean red blood cell volume fL 88.03 ± 0.74 88.15 ± 1.27 88.51 ± 1.74 86.47 ± 0.81
Mean corpuscular Hb pg 17.34 ± 0.19 17.70 ± 0.31 17.75 ± 0.22 17.58 ± 0.07
Mean corpuscular Hb concentration g/L 19.71 ± 0.25 20.16 ± 0.40 20.12 ± 0.40 20.39 ± 0.16
Platelets 109/L 1205.61 ± 26.53 1149.19 ± 29.80 1145.28 ± 67.30 1125.36 ± 18.04
Mean platelet cell volume fL 8.12 ± 0.12 8.46 ± 0.17 8.26 ± 0.19 8.11 ± 0.13
Data are expressed as mean ± SEM.
(b)
Unit
Treatment for 28 days
Control 50% methanolic extract of Orthosiphon stamineus
1250mg/kg 2500mg/kg 5000mg/kg
Female
White blood cell count 109/L 7.66 ± 0.96 6.77 ± 0.43 6.31 ± 0.72 7.24 ± 0.35
Neutrophils 109/L 1.69 ± 0.32 1.63 ± 0.18 1.47 ± 0.16 1.78 ± 0.18
Lymphocytes 109/L 5.35 ± 0.68 4.62 ± 0.52 4.37 ± 0.55 4.26 ± 0.95
Monocytes 109/L 0.34 ± 0.08 0.30 ± 0.09 0.31 ± 0.05 0.30 ± 0.03
Eosinophils 109/L 0.02 ± 0.01 0.02 ± 0.00 0.02 ± 0.00 0.01 ± 0.00
Basophils 109/L 0.27 ± 0.07 0.20 ± 0.04 0.22 ± 0.04 0.19 ± 0.02
Red blood cell count 1012/L 7.76 ± 0.17 7.79 ± 0.06 7.25 ± 0.36 7.48 ± 0.19
Hemoglobin g/L 14.16 ± 0.14 14.44 ± 0.12 13.56 ± 0.29 13.64 ± 0.50
Hematocrit % 0.71 ± 0.01 0.71 ± 0.00 0.67 ± 0.02 0.68 ± 0.01
Mean red blood cell volume fL 89.47 ± 1.64 90.93 ± 0.52 87.80 ± 1.95 91.09 ± 1.20
Mean corpuscular Hb pg 18.30 ± 0.25 18.54 ± 0.14 18.01 ± 0.23 18.35 ± 0.56
Mean corpuscular Hb concentration g/L 20.14 ± 0.18 20.41 ± 0.18 19.85 ± 0.23 20.16 ± 0.56
Platelets 109/L 1054.14 ± 57.95 1021.22 ± 14.30 987.46 ± 21.65 1035.83 ± 55.79
Mean platelet cell volume fL 7.99 ± 0.10 7.78 ± 0.19 7.23 ± 036 7.55 ± 0.10
Data are expressed as mean ± SEM.
of chronic diseases, DNA damage, mutagenesis, carcinogene-
sis, and inhibition of pathogenic bacterial growth [21]. Hence,
as a potent antioxidant, it is not surprising that Orthosiphon
stamineus is effective in treating various oxidative stress-
related chronic diseases such as diabetes, alcohol-induced
stomach ulcer, and CCl
4
-induced liver damage.
In acute 14-day toxicity study, a limited dose was selected
and performed on the experimental rats. Its purpose was
to determine a proper range of doses to be used in the
subsequent subchronic 28-day toxicological study [19]. In this
experiment, a single dose of 5000mg/kg MEOS was given
orally to five female Sprague-Dawley rats. No significant
mortality or alteration in the behaviour patterns of the treated
rats was observed compared to their respective controls.
During the subchronic 28-day toxicity study, the rats
were treated orally with different doses of MEOS (1250,
2500, and 5000mg/kg/day) for 28 days. The results obtained
were comparable to those in the acute toxicity study. Both
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Table 3: Biochemical values of male and female rats treated with 50% methanolic extract of Orthosiphon stamineus for 28 days.
Unit
Treatment for 28 days
Control 50% methanolic extract of Orthosiphon stamineus
1250mg/kg 2500mg/kg 5000mg/kg
Male
Aspartate transaminase (AST) U/L 122.74 ± 2.19 131.94 ± 3.53 126.79 ± 9.40 121.81 ± 2.45
Alanine aminotransferase (ALT) U/L 64.51 ± 2.98 62.43 ± 2.59 64.50 ± 3.86 65.22 ± 2.73
Urea U/L 6.31 ± 0.34 6.65 ± 0.34 6.50 ± 0.40 6.74 ± 0.14
Creatinine 𝜇mol/L 40.56 ± 0.81 39.59 ± 0.30 41.08 ± 1.16 39.33 ± 0.45
Alkaline phosphatase (ALP) 𝜇mol/L 300.56 ± 7.18 309.63 ± 10.08 309.50 ± 11.49 316.86 ± 13.42
Bilirubin mmol/L 1.80 ± 0.00 1.80 ± 0.00 1.80 ± 0.00 1.80 ± 0.00
Sodium g/L 142.53 ± 0.36 142.53 ± 0.22 141.96 ± 0.58 142.22 ± 0.31
Potassium g/L 4.69 ± 0.12 4.64 ± 0.06 4.72 ± 0.07 4.65 ± 0.08
Chlorine g/L 102.72 ± 0.60 102.71 ± 0.33 103.75 ± 0.28 103.53 ± 0.61
Female
Aspartate transaminase (AST) U/L 127.83 ± 2.51 127.72 ± 4.98 122.61 ± 10.41 117.28 ± 8.10
Alanine aminotransferase (ALT) U/L 54.33 ± 2.32 52.17 ± 3.32 53.78 ± 3.41 52.94 ± 1.72
Urea U/L 7.83 ± 0.46 7.39 ± 0.08 8.00 ± 0.39 7.19 ± 0.29
Creatinine 𝜇mol/L 50.83 ± 2.41 47.72 ± 1.11 47.11 ± 1.27 44.50 ± 0.25
Alkaline phosphatase (ALP) 𝜇mol/L 247.50 ± 8.33 249.72 ± 21.56 250.22 ± 21.23 267.33 ± 9.95
Bilirubin mmol/L 1.80 ± 0.00 1.80 ± 0.00 1.80 ± 0.00 1.80 ± 0.00
Sodium g/L 142.83 ± 0.60 142.94 ± 0.20 141.44 ± 0.20 141.11 ± 0.26
Potassium g/L 4.23 ± 0.14 4.19 ± 0.15 4.04 ± 0.11 4.14 ± 0.15
Chlorine g/L 102.50 ± 0.62 103.39 ± 0.54 103.17 ± 0.51 103.83 ± 0.46
Data are expressed as mean ± SEM.
control and treated rats of both sexes appeared generally
healthy during and throughout the experimental period. No
mortality was recorded and no toxicity signs were detected
in any of the treated rats. Both evaluation of the acute and
subchronic toxicity of MEOS had indicated that a single
oral administration of MEOS up to 5000mg/kg dose caused
neither visible signs of toxicity nor mortality to experimental
rats. Hence, the LD
50
of MEOS determined is more than
5000mg/kg.
Generally, an increase or decrease in bodyweight of an
animal has been used as an indicator of adverse effect of drugs
and chemicals [22]. In our study, all the treated animals sur-
vived beyond the observation period.Thebodyweight of both
control and treatment groups increased gradually throughout
the experimental period with no significant difference. The
increase in bodyweight was not significantly different as
compared to the control group, in both acute and subchronic
toxicity studies. All the rats at each dosage level continued to
gain weight throughout the experimental period, suggesting
that growth inhibition did not occur during this course of
repeated dosage.
In addition to bodyweight, relative organ weight has also
been used as another basic indicator to determine whether
the rats have been exposed to harmful agents [19, 22]. Their
organs will tend to swell or damage if they were subjected to
toxic substances. This will subsequently alter their organ-to-
bodyweight ratios as compared to the respective controls. In
the present study, the relative organ weights of liver, lungs,
spleen, sex organs, heart, and kidneys in all the treated male
and female rats were not significantly different (𝑃 < 0.05)
from those of the control groups.
Analysis of blood parameters in animal studies could be
very useful when evaluating the risk of human toxicity as the
changes in the haematological system provide a predictive
value for toxicity [18].These blood parameters are often called
haematological parameters. Several important haematolog-
ical parameters were selected in this study to evaluate the
toxicity ofMEOS. From the results, the haematological profile
of all the treated rats showed no significant differencewith the
control group (Table 2).This indicated that theMEOS did not
affect the haematopoiesis system of the treated rats.
Several important biochemical parameters were also
included in this toxicity study. These biological parameters
are indicators for organ toxicity. For example, kidney func-
tions were evaluated by means of serum urea and creatinine.
Increase of blood creatinine has been shown to be a good
indicator of negative impact in kidney functions [23]. While
the increase levels of AST andALT in the blood are associated
with damage of hepatic cells [24, 25]. The results of the
experiment suggested that the kidney and liver functions
were not altered for both the treated male and female
rats. There were no statistically significant differences in
creatinine, AST, and ALT levels between controls and treated
animals at any dosage levels. Hence, these findings suggest
that MEOS does not cause any hepatotoxicity and kidney
damage to the rats. Both these organs were selected because
kidneys and liver are the first organs to show toxicity when
the rats are exposed to potential toxic substances. Based on
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the statistical analyses of these biochemical parameters, no
significant difference was observed in any of the parameters
tested for either the treated or normal rats (Table 3).
Histopathological studies were conducted on vital organs
of all the rats. According to Wang et al., impaired organs
often have abnormal atrophy [26]. However, from our
results, no related histopathological changes were observed.
Gross examination in necropsy andmicroscopic examination
revealed no changes that might be due to the administration
of MEOS (data not shown). No significant changes or
damages were observed in the morphology of all the isolated
vital organs, either from the rats treated with MEOS or
control rats (data not shown). The isolated organs showed
normal architecture. These results again suggested that daily
repeated oral administration of MEOS did not cause any
detrimental changes or morphological disturbances to the
rats or to their vital organs. The no-observed-adverse-effect
level (NOAEL) of MEOS determined was 5000mg/kg body-
weight/day (>3000mg/kg bodyweight/day) and considered
to be a non-hazard compound.
5. Conclusion
This finding is comparable with Mohamed et al.’s [19] and
Abdullah et al.’s (2009) in which O. stamineus alcoholic
extract did not show any toxic effect in rats during both
acute and subchronic studies. Daily oral administration of
50% methanolic extract of O. stamineus (MEOS) at doses
of 1250, 2500, and 5000mg/kg to both male and female
Sprague-Dawley rats for 28 days did not result in mortality
and was not associated with adverse effects as reflected in
the observation of general condition, growth, body and organ
weights and hematological and biochemical values. Thus, its
oral lethal dose for both male and female rats is in excess
of 5000mg/kg. There were no abnormalities in necropsy
and histopathological findings. An NOAEL from the present
study was determined to be 5000mg/kg per day for rats
under the condition tested. Further investigation on the
preclinical and clinical studies of the extract will be necessary
to determine a safe dose before it becomes a potential drug
and to protect the population from possible toxic effects
of MEOS. It would be interesting to assess the toxic effect
of the compounds found in MEOS such as eupatorin and
sinensetin.
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